Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
AZD1163 · 1 trial · 1 indication
Change from baseline in DAS28-CRP at Week 12.
| Arm | Type | Description |
|---|---|---|
| AZD1163 Dose 1 | EXPERIMENTAL | Participants will receive subcutaneous (SC) injection of AZD1163 Dose 1 in combination with SoC (csDMARDs or TNFi +/- csDMARD) until Week 24. |
| AZD1163 Dose 2 | EXPERIMENTAL | Participants will receive SC injection of AZD1163 Dose 2 in combination with SoC (csDMARDs or TNFi +/- csDMARD) until Week 24. |
| AZD1163 Dose 3 | EXPERIMENTAL | Participants will receive SC injection of AZD1163 Dose 3 in combination with SoC (csDMARDs or TNFi +/- csDMARD) until Week 24. |
| Placebo | PLACEBO_COMPARATOR | Participants will receive SC injection of placebo matched with AZD1163 dose in combination with SoC (csDMARDs or TNFi +/- csDMARD) until Week 24. |
| Name | Type | Description |
|---|---|---|
| AZD1163 | DRUG | Participants will receive SC injection of one of three different doses of AZD1163 in combination with SoC (csDMARD or TNFi +/- csDMARDSoC) until Week 24. |
| Placebo | OTHER | Participants will receive SC injection of placebo matched to AZD1163 in combination with SoC (csDMARD or TNFi +/- csDMARDSoC) until Week 24. |
* Inclusion * Diagnosed with adult-onset RA as defined by the 2010 ACR/EULAR classification criteria for at least 12 weeks prior to screening. * Moderately-to-severely active RA as defined by: a. \>= 6 swollen joints on 66SJC and \>= 6 tender joints on 68TJC; b. CRP \> upper limit of normal. ...
Top 20 of 31 competitors
AZD1163 is an investigational small molecule being developed by AstraZeneca PLC for the treatment of rheumatoid arthritis. It is currently in Phase 2 clinical development and has not been approved for any indication. AstraZeneca trades on the Nasdaq under the ticker AZN.
AZD1163 is being studied as a treatment for rheumatoid arthritis, an inflammatory joint disease. It is an investigational therapy in Phase 2 testing and is not yet approved for use in rheumatoid arthritis or any other condition. Its safety and efficacy in patients are still being evaluated in clinical trials.
AZD1163 is developed by AstraZeneca PLC, which trades under the ticker AZN. AstraZeneca is running the clinical program for the drug in rheumatoid arthritis, including a Phase 2 study that is currently recruiting participants across multiple countries.
AZD1163 is in Phase 2 clinical development. It is an investigational small molecule for rheumatoid arthritis and has not received FDA approval. The Phase 2 trial is currently recruiting, and no Phase 3 studies or completed trials for this drug have been reported.
AZD1163 is being evaluated in one clinical trial, NCT07276581, titled A Study to Investigate Efficacy and Safety of AZD1163 in Participants With Rheumatoid Arthritis. This Phase 2 study is currently recruiting and plans to enroll 320 participants aged 18 years and older across sites in the United States, Europe, Asia, Latin America, and other regions.
Yes. The Phase 2 trial of AZD1163 in rheumatoid arthritis, NCT07276581, is a randomized, double-blind, placebo-controlled study. It plans to enroll 320 participants with rheumatoid arthritis and is currently recruiting. The trial does not select participants based on a biomarker.